Core Points - The report details the fundraising and usage of funds by Shanghai MicroPort MedBot (Group) Co., Ltd. for the first half of 2025, ensuring compliance with relevant regulations [1][10] - The company raised a total of RMB 832.14 million from its initial public offering (IPO) in 2019 and RMB 1.81 billion from a subsequent issuance to specific investors in 2022 [1][10] - As of June 30, 2025, the remaining balance of the funds raised from the IPO was RMB 25.49 million, while the balance from the 2022 issuance was RMB 1.17 billion [1][10] Fundraising Overview - The company issued 18 million shares at RMB 46.23 per share in 2019, raising RMB 832,140,000, with a net amount of RMB 729,658,867.93 after deducting issuance costs [1][10] - In 2022, the company issued 10,748,106 shares at RMB 168.33 per share, raising RMB 1,809,228,682.98, with a net amount after costs not specified [1][10] Fund Usage and Balance - As of June 30, 2025, the company had used RMB 166,937.06 from the IPO funds, primarily for the development of medical devices [1][10] - The remaining balance of the IPO funds was RMB 25,494,864.34, while the 2022 issuance funds had a balance of RMB 1,174,150,962.83 after using RMB 89,446,375.42 during the reporting period [1][10] Fund Management - The company has established a dedicated fund management system to ensure that the raised funds are used appropriately and in compliance with regulations [1][10] - The funds are stored in special accounts, and the company has adhered to strict approval procedures for fund usage [1][10] Project Updates - The company has not reported any early investments or replacements of funds for the projects during the reporting period [1][10] - There were no instances of using idle funds for temporary working capital during this period [1][10] Future Plans - The company plans to extend the construction period for the "Global Headquarters and Innovation and Industrialization Base Project" to September 2027 due to various construction challenges [1][10][12]